ZNF703 gene amplification at 8p12 specifies luminal B breast cancer
Luminal B breast cancers represent a fraction of oestrogen receptor (ER)‐positive tumours associated with poor recurrence‐free and disease‐specific survival in all adjuvant systemic treatment categories including hormone therapy alone. Identification of specific signalling pathways driving luminal B...
Saved in:
Published in | EMBO molecular medicine Vol. 3; no. 3; pp. 153 - 166 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
01.03.2011
WILEY‐VCH Verlag EMBO Press Wiley Open Access WILEY-VCH Verlag |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Luminal B breast cancers represent a fraction of oestrogen receptor (ER)‐positive tumours associated with poor recurrence‐free and disease‐specific survival in all adjuvant systemic treatment categories including hormone therapy alone. Identification of specific signalling pathways driving luminal B biology is paramount to improve treatment. We have studied 100 luminal breast tumours by combined analysis of genome copy number aberrations and gene expression. We show that amplification of the
ZNF703
gene, located in chromosomal region 8p12, preferentially occurs in luminal B tumours. We explored the functional role of ZNF703 in luminal B tumours by overexpressing ZNF703 in the MCF7 luminal cell line. Using mass spectrometry, we identified ZNF703 as a co‐factor of a nuclear complex comprising DCAF7, PHB2 and NCOR2. ZNF703 expression results in the activation of stem cell‐related gene expression leading to an increase in cancer stem cells. Moreover, we show that ZNF703 is implicated in the regulation of ER and E2F1 transcription factor. These findings point out the prominent role of ZNF703 in transcription modulation, stem cell regulation and luminal B oncogenesis.
→See accompanying Closeup by Vessela Kristensen DOI
https://doi.org/10.1002/emmm201100128 |
---|---|
Bibliography: | Contributed equally. PMCID: PMC3395112 Present address: Fondation Synergie Lyon Cancer, Centre Léon Bérard, Lyon, France Present address: MaRS Centre Toronto Medical Discovery district, Toronto, Ontario, Canada Present address: Texas Tech University, Lubbock, Texas, USA Present address: Génétique Médicale, Hôpital de la Timone, Marseille, France Present address: Faculté de Médecine, CRN2M, UMR6231, IFR Jean Roche, Secteur Nord, Université de la Méditerranée, Marseille, France Present address: Unité de Pharmacologie Clinique Expérimentale et Thérapeutique, CHU La Timone, Marseille, France |
ISSN: | 1757-4676 1757-4684 |
DOI: | 10.1002/emmm.201100121 |